CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $265.55M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 3.78: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.79BCNY265.55M · vs all stocks (USD)
Trailing P/E
96.60xRevenue (TTM)
563.66MCNY83.71M · vs all stocks (USD)
Profit Margin
3.24%Beta
0.0600xvs all stocks
52-Week Change
-39.52%vs all stocks
Market Capitalization
1.79BCNY265.55M · vs all stocks (USD)
Enterprise Value
1.38BCNY205.61M · vs all stocks (USD)
Trailing P/E
96.60xPEG Ratio
0.4322xPrice to Sales (TTM)
3.20xPrice to Book (MRQ)
1.08xEnterprise to Revenue
2.46xEnterprise to EBITDA
58.80xGross Margin
78.48%Profit Margin
3.24%Operating Margin
8.05%Return on Assets (TTM)
0.32%Return on Equity (TTM)
1.14%Revenue (TTM)
563.66MCNY83.71M · vs all stocks (USD)
Revenue per Share (TTM)
1.60CNYUpdated Aug 20, 2026Quarterly Revenue Growth
18.30%Gross Profit (TTM)
436.71MCNY64.86M · vs all stocks (USD)
EBITDA (TTM)
49.45MCNY7.34M · vs all stocks (USD)
Net Income (TTM)
18.27MCNY2.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
221.60%Operating Cash Flow (TTM)
92.20MCNY13.69M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
92.18MCNY13.69M · vs all stocks (USD)
5-Year Average Dividend Yield
0.64%vs all stocks
Payout Ratio
57.92%Minority Interest (Equity)
-1.26MCNYFY2025 · Dec 31, 2025Revenue
544.04MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
125.12MCNYFY2025 · Dec 31, 2025Gross Profit
418.92MCNYFY2025 · Dec 31, 2025Operating Income
5.32MCNY790.01K · vs all stocks (USD)
Pre-tax Income
18.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
3.24MCNYFY2025 · Dec 31, 2025Net Income
15.33MCNYFY2025 · Dec 31, 2025EBIT
23.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
49.45MCNYFY2025 · Dec 31, 2025Research & Development
30.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
317.81MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.80MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0442CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0442CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
352.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
352.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.33MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
244.96KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
595.07KCNYFY2025 · Dec 31, 2025Free Cash Flow
-124.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
310.79MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.33MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.62MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-17.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-124.78MCNYFY2025 · Dec 31, 2025Net Acquisitions
139.02MCNYFY2025 · Dec 31, 2025Purchase of Investments
-212.80KCNYFY2025 · Dec 31, 2025Sale of Investments
13.01MCNYFY2025 · Dec 31, 2025Other Investing Activity
-23.06MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
3.97MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
890.10MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-924.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.47MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.88MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-55.87MCNYFY2025 · Dec 31, 2025Shares Outstanding
373.27MSharesUpdated Aug 20, 2026Float Shares
227.73MSharesUpdated Aug 20, 2026% Held by Insiders
33.54%vs all stocks
% Held by Institutions
0.03%vs all stocks
Total Cash (MRQ)
331.66MCNY49.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9340CNYUpdated Aug 20, 2026Total Debt (MRQ)
58.20MCNY8.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0365xCurrent Ratio (MRQ)
2.00xBook Value per Share (MRQ)
4.49CNYUpdated Aug 20, 2026Total Assets
1.93BCNY286.34M · vs all stocks (USD)
Total Current Assets
621.18MCNYFY2025 · Dec 31, 2025Total Liabilities
369.61MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.31BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
43.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
326.47MCNYFY2025 · Dec 31, 2025Cash
296.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
14.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
310.79MCNYFY2025 · Dec 31, 2025Other Short-term Investments
49.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
115.91MCNYFY2025 · Dec 31, 2025Inventory
32.81MCNYFY2025 · Dec 31, 2025Accounts Payable
8.89MCNYFY2025 · Dec 31, 2025Short-term Debt
20.63MCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.59MCNYFY2025 · Dec 31, 2025Long-term Debt
3.39MCNYFY2025 · Dec 31, 2025Common Stock (Book)
373.27MCNYFY2025 · Dec 31, 2025Retained Earnings
515.28MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.56BCNY231.45M · vs all stocks (USD)
Treasury Stock
149.50MCNYFY2025 · Dec 31, 202552-Week Low
4.26CNYUpdated Aug 20, 202652-Week High
9.35CNYUpdated Aug 20, 202652-Week Change
-39.52%vs all stocks
Beta
0.0600xvs all stocks
50-Day MA
4.78CNYUpdated Aug 20, 2026200-Day MA
7.05CNYUpdated Aug 20, 2026Avg 10-Day Volume
2.06MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.43MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0500CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: 0.03
Financial Health
Altman Z-Score 3.78: safe zoneNotable
Altman Z-Score: 3.78
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $265.55M, lower than 95% of all stocks globallySignificant
Market cap (USD): 265,548,512.046Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule